Sobi North America, a subsidiary of Swedish Orphan Biovitrum AB, announced that the U.S. Food and Drug Administration has granted authorization for their arthritis drug to be used in the treatment of hospitalized COVID-19 patients at high risk. This comes as an exciting development given the drug’s previous approval in the European Union for treating COVID-19. It’s like a new tool in the shed that is proving to be effective against the virus! The FDA’s decision demonstrates their recognition of the potential benefit this drug can provide to those who are more vulnerable to severe illness from COVID-19. With the authorization in place, high-risk patients now have access to this additional treatment option. Perhaps further research could explore whether this drug could be effective in treating mild or moderate COVID-19 cases as well. If you want to dive deeper into the details, check out the article linked below!
